NCT04648709

Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 73 (actual)
• Sponsor: Centre Hospitalier Universitaire de Saint Etienne · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

Current data in the literature demonstrate that the immune response to CoV-2-SARS is much more complex than initially assumed. In fact, beyond the humoral response, including the existence of neutralizing CAs, the adaptive lymphocyte T-type immune response also appears to play an important role in controlling the infection and reducing the severity of the disease. At this stage, the analysis of this T response is still rudimentary and underdeveloped, but it seems crucial to be able to analyze it effectively in COVID-19 patients, which could help predict the evolution of the infection. It is also currently difficult to know the evolution of this response over time and especially after the resolution of the infection. To this end, we will analyze the T lymphocyte response (ELISPOT and QUANTIFERON) based on the secretion of IFN (Th1) and IL-4 (Th2) by CoV-2-SARS specific T cells from COVID-19 patients. We will compare the T response to the quality of the systemic and mucosal humoral response. Finally, we will evaluate in parallel two new biomarkers of the severity of COVID-19: plasma calprotectin and the presence of antibodies to type 1 IFN antibodies.

Conditions

• Covid19

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	ELISPOT	measure of immune response by ELISPOT
DIAGNOSTIC_TEST	QUANTIFERON	measure of immune response by QUANTIFERON

Timeline

• Start date: 2021-03-09
• Primary completion: 2022-09-26
• Completion: 2023-12-11
• First posted: 2020-12-01
• Last updated: 2023-12-20

Locations

1 site across 1 country: France